Patients With CancerPhase 1/2NCT01242943
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
A Phase 1/2 study testing 131I-L19SIP Radioimmunotherapy (RIT) in people with Patients With Cancer, run by Philogen S.p.A. at 4 sites in 2 countries.
Trial summary
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Patients With Cancer
- What is being tested?
- 131I-L19SIP Radioimmunotherapy (RIT)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 4 sitesin 2 countries
- Study dates
- Nov 2008to May 2011
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with cancer, with progressive disease in pre-study period, refractory to conventional standard treatments.
- Histologically/cytologically confirmed diagnosis of cancer, preferably lung cancer, prostate cancer and colorectal cancer (CRC). At least one measurable (minimum 2.0 cm), non irradiated lesion defined according to modified RECIST criteria, i.e. whenever the measurable disease is restricted to a solitary lesion, its neoplastic nature need not to be confirmed by cytology/histology.
- ECOG performance status grade 0 or 1.
- Age ≥18 and ≤ 75 years.
- Adequate haematological, liver and renal function (haemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1.50 x 10^9/L; platelets ≥ 100 x 10^9/L, bilirubin within UNL; alkaline phosphatase≤ 2.5 x UNL; ALT, AST ≤ UNL or ≤ 2.5 x UNL in case of liver metastases; albumin ≥ 2.5 g/dL; creatinine ≤ UNL.
- All acute toxic effects (excluding alopecia) of any prior therapy (including surgery radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v.3.0) Grade ≤ 1.
Show all 12Show fewer
- Negative serum pregnancy test for females of childbearing potential within 14 days of starting treatment.
- If of childbearing potential, agreement to use adequate contraceptive methods (e.g. oral contraceptives, condoms, or other adequate barrier controls, intrauterine contraceptive devices, or sterilization) beginning at the screening visit and continuing until 3 months following last treatment with study drug.
- Evidence of a personally signed and dated IEC-approved Informed Consent indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the study.
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
- Life expectancy of at least 3 months.
- Signed and dated informed consent.
Who cannot join
- Chemotherapy, radiation, hormonotherapy (with the exception of a gradual titration of LHRH agonists) or immunotherapy or participation in any investigational drug study within 4 weeks of study entry (6 weeks in case of prior nitroureas chemotherapy).
- Prior radiation dose > 30% of bone marrow volume.
- Presence of cirrhosis or active hepatitis.
- Presence of serious cardiac (congestive heart failure, heart insufficiency > grade II NYHA, angina pectoris, myocardial infarction within one year prior to study entry, uncontrolled hypertension or arrhythmia), neurological or psychiatric disorders.
- Presence of uncontrolled intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study.
- Recovery from major trauma including surgery within 4 weeks of administration of study treatment.
Show all 10Show fewer
- Pregnancy or lactation or unwillingness to use adequate method of birth control.
- Active infection or incomplete wound healing.
- Known history of allergy to intravenously administered proteins / peptides / antibodies.
- Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
Trial locations and contacts
4 sites in 2 countries.
4 sites in 2 countries
Italy3 sites
Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Meldola (Fc)
Meldola
University Hospital Pisa
Pisa, Tuscany, 56126
Irccs Ospedale Casa Sollievo Della Sofferenza - San Giovanni Rotondo
San Giovanni Rotondo (FG)
United Kingdom1 site
University College London, UCL Cancer Institute
London
About this study
Official title: A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
Read the detailed description
The L19SIP antibody is a fully human antibody, capable of preferential localization around tumor blood vessels while sparing normal tissues. The formation of new blood vessels is a rare event in the adult (exception made for the female reproductive cycle), but is a pathological feature of most aggressive types of cancer. The study aims at determining the therapeutic potential of the L19SIP antibody in SIP format, labelled with the radionuclide 131I, for the treatment of patients with different cancer types. The study follows a Phase I study performed with 131I-L19SIP in over 30 patients with cancer, which has shown an excellent tolerability at radioactive doses as high as 150 mCi and therapeutic benefit for some patients enrolled in the study.
- Conditions
- Patients With Cancer
- Being tested
- 131I-L19SIP Radioimmunotherapy (RIT)
- Keywords
- I131, L19, antibody, monoclonal, tumour targeting, radioimmunotherapy, cancer
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
131I-L19SIP Radioimmunotherapy (RIT)Drug
Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.
Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167.
| Study group | Role | What they receive |
|---|---|---|
| L19SIP I131 | Experimental | Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.
Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I. Receives: Drug: 131I-L19SIP Radioimmunotherapy (RIT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase I: Maximum tolerated dose (MTD)
Establishment of the maximum tolerated dose (MTD) and the recommended dose (RD) for the radiolabelled L19SIP monoclonal antibody.
Measured: 4 weeks
Phase II: Antitumour activity
Investigation of the antitumour activity of 131I-L19SIP at the RD, in patients with advanced cancer.
Measured: 1- 14 months
Secondary outcomes (5)
Phase I: Study of the variation of radioactivity of 131I in whole blood, at several time intervals (Pharmacokinetics)
Evaluation of the pharmacokinetics of 131IL19SIP.
Measured: 2 days
Phase II: Safety profile
Determination of the overall safety profile of the iodinated antibody characterized by type, frequency, severity, timing and relationship to study therapy of adverse events and laboratory abnormalities in the first and following cycles in all patients receiving a therapeutic dose.
Measured: 30 days/ administration
Phase II: Overall Response Rate (ORR)
Evaluation of the overall Response Rate (ORR) for all patients having received a therapeutic dose.
Measured: 6 and 12 months
Phase II: Progression free survival (PFS)
Evaluation of the progression free survival (PFS) for all patients having received a therapeutic dose.
Measured: 6 and 12 months
Phase II: Survival rate
Evaluation of the survival rate at 6 and 12 months and overall survival time for all patients having received a therapeutic dose.
Measured: 6 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2010 (estimated)
- Study startNov 2008
- Primary completionFeb 2011
- Study completionMay 2011
Why it stopped: With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients With CancerStudies of the same condition, open and under way.
- More trials run by Philogen S.p.A.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Philogen S.p.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Giuliano Mariani, Prof, Principal investigator, University Hospital Pisa, ItalyTim Meyer, Dr, Principal investigator, University College London (UCL) Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01242943
- Sponsor's protocol ID
- PH-L19SIPI131-07/07
- Status last verified
- Nov 2011
- First submitted
- 16 Nov 2010
- Last updated
- 22 Nov 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Nov 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER
- ClinicalTrials.gov ID
- NCT01242943
- Acronym / sponsor ID
- PH-L19SIPI131-07/07
- Conditions
- Patients With Cancer
- Keywords
- I131, L19, antibody, monoclonal, tumour targeting, radioimmunotherapy, cancer
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Philogen S.p.A.Industry (pharma, biotech, devices)
- Study start
- Nov 2008
- Primary completion
- Feb 2011 (actual)
- Study completion
- May 2011 (actual)
- First posted
- 17 Nov 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
Detailed description
The L19SIP antibody is a fully human antibody, capable of preferential localization around tumor blood vessels while sparing normal tissues. The formation of new blood vessels is a rare event in the adult (exception made for the female reproductive cycle), but is a pathological feature of most aggressive types of cancer. The study aims at determining the therapeutic potential of the L19SIP antibody in SIP format, labelled with the radionuclide 131I, for the treatment of patients with different cancer types. The study follows a Phase I study performed with 131I-L19SIP in over 30 patients with cancer, which has shown an excellent tolerability at radioactive doses as high as 150 mCi and therapeutic benefit for some patients enrolled in the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| L19SIP I131 | Experimental | Drug: 131I-L19SIP Radioimmunotherapy (RIT)Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer. Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Patients with cancer, with progressive disease in pre-study period, refractory to conventional standard treatments.
- Histologically/cytologically confirmed diagnosis of cancer, preferably lung cancer, prostate cancer and colorectal cancer (CRC). At least one measurable (minimum 2.0 cm), non irradiated lesion defined according to modified RECIST criteria, i.e. whenever the measurable disease is restricted to a solitary lesion, its neoplastic nature need not to be confirmed by cytology/histology.
- ECOG performance status grade 0 or 1.
- Age ≥18 and ≤ 75 years.
- Adequate haematological, liver and renal function (haemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1.50 x 10^9/L; platelets ≥ 100 x 10^9/L, bilirubin within UNL; alkaline phosphatase≤ 2.5 x UNL; ALT, AST ≤ UNL or ≤ 2.5 x UNL in case of liver metastases; albumin ≥ 2.5 g/dL; creatinine ≤ UNL.
Key exclusion criteria (10 listed)
- Chemotherapy, radiation, hormonotherapy (with the exception of a gradual titration of LHRH agonists) or immunotherapy or participation in any investigational drug study within 4 weeks of study entry (6 weeks in case of prior nitroureas chemotherapy).
- Prior radiation dose > 30% of bone marrow volume.
- Presence of cirrhosis or active hepatitis.
- Presence of serious cardiac (congestive heart failure, heart insufficiency > grade II NYHA, angina pectoris, myocardial infarction within one year prior to study entry, uncontrolled hypertension or arrhythmia), neurological or psychiatric disorders.
- Presence of uncontrolled intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 131I-L19SIP Radioimmunotherapy (RIT)Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy. Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167. | Drug | L19SIP I131 |
Primary outcome
Phase I: Maximum tolerated dose (MTD)
Time frame: 4 weeks
Establishment of the maximum tolerated dose (MTD) and the recommended dose (RD) for the radiolabelled L19SIP monoclonal antibody.
Phase II: Antitumour activity
Time frame: 1- 14 months
Investigation of the antitumour activity of 131I-L19SIP at the RD, in patients with advanced cancer.
5 secondary outcomes
Phase I: Study of the variation of radioactivity of 131I in whole blood, at several time intervals (Pharmacokinetics)
Time frame: 2 days
Phase II: Safety profile
Time frame: 30 days/ administration
Phase II: Overall Response Rate (ORR)
Time frame: 6 and 12 months
Phase II: Progression free survival (PFS)
Time frame: 6 and 12 months
Phase II: Survival rate
Time frame: 6 and 12 months
Results and safety
The study was stopped early (reason given: With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Nov 2011.
Related trials for Patients With Cancer
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Giuliano Mariani, Prof principal investigator
University Hospital Pisa, Italy
Tim Meyer, Dr principal investigator
University College London (UCL) Cancer Institute
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing 131I-L19SIP Radioimmunotherapy (RIT) in people with Patients With Cancer, run by Philogen S.p.A. at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Italy, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase I: Maximum tolerated dose (MTD) (time frame: 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2011.